OTCMKTS:CSLLY CSL (CSLLY) Stock Price, News & Analysis $81.84 -0.89 (-1.08%) As of 02/21/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort Interest About CSL Stock (OTCMKTS:CSLLY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CSL alerts:Sign Up Key Stats Today's Range$81.65▼$82.5350-Day Range$80.54▼$89.5852-Week Range$77.37▼$109.00Volume61,598 shsAverage Volume89,962 shsMarket Capitalization$79.25 billionP/E RatioN/ADividend Yield1.65%Price TargetN/AConsensus RatingStrong Buy Company OverviewCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Read More… CSL Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreCSLLY MarketRank™: CSL scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for CSL.Read more about CSL's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth14.25% Earnings GrowthEarnings for CSL are expected to grow by 14.25% in the coming year, from $3.58 to $4.09 per share.Price to Earnings Growth RatioCSL has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCSL has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the outstanding shares of CSL have been sold short.Short Interest Ratio / Days to CoverCSL has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CSL has recently decreased by 72.00%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldCSL pays a meaningful dividend of 1.62%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthCSL does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, CSL will have a dividend payout ratio of 33.01% next year. This indicates that CSL will be able to sustain or increase its dividend.Read more about CSL's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the outstanding shares of CSL have been sold short.Short Interest Ratio / Days to CoverCSL has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CSL has recently decreased by 72.00%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.43 News SentimentCSL has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CSL this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added CSL to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CSL insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.03% of the stock of CSL is held by institutions.Read more about CSL's insider trading history. Receive CSLLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter. Email Address CSLLY Stock News HeadlinesCSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)February 20 at 9:13 AM | prnewswire.comCSL Limited Director Updates Shareholding PositionFebruary 19 at 12:37 AM | tipranks.comHere’s how you could profit from Elon’s NVIDIA partnership"Elon's #1 AI Stock" SET TO SOAR Forget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful. After all, ChatGPT just works online... While Elon's AI works in the real world.February 22, 2025 | Behind the Markets (Ad)CSL Limited Issues Unquoted Equity Securities for Employee IncentiveFebruary 19 at 12:37 AM | tipranks.comEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineFebruary 14, 2025 | prnewswire.comEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 VaccineFebruary 14, 2025 | businesswire.comRBC Capital Remains a Hold on CSL (CMXHF)February 14, 2025 | markets.businessinsider.comCSL Limited Earnings Call Highlights Growth and ChallengesFebruary 13, 2025 | tipranks.comSee More Headlines CSLLY Stock Analysis - Frequently Asked Questions How have CSLLY shares performed this year? CSL's stock was trading at $87.56 on January 1st, 2025. Since then, CSLLY shares have decreased by 6.5% and is now trading at $81.84. View the best growth stocks for 2025 here. How do I buy shares of CSL? Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today2/21/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:CSLLY CUSIPN/A CIK1274152 Webwww.csl.com.au Phone(139) 389-1911Fax61-3-9389-1434Employees32,698Year Founded1904Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio22.86 P/E Growth1.6Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.58 Current Ratio2.18 Quick Ratio0.97 Sales & Book Value Annual Sales$14.80 billion Price / Sales5.36 Cash Flow$3.91 per share Price / Cash Flow20.95 Book Value$20.07 per share Price / Book4.08Miscellaneous Outstanding Shares968,410,000Free FloatN/AMarket Cap$79.25 billion OptionableNot Optionable Beta0.75 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (OTCMKTS:CSLLY) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CSL Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CSL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.